Acasti Pharma (NASDAQ: ACST) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Acasti Pharma to related companies based on the strength of its analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk.
This is a summary of recent ratings and recommmendations for Acasti Pharma and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Acasti Pharma Competitors||3746||10967||24987||825||2.56|
Earnings & Valuation
This table compares Acasti Pharma and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Acasti Pharma||$30,000.00||-$16.77 million||-1.34|
|Acasti Pharma Competitors||$2.03 billion||$140.19 million||-2.18|
Acasti Pharma’s competitors have higher revenue and earnings than Acasti Pharma. Acasti Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Acasti Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Acasti Pharma Competitors||-2,632.88%||-80.14%||-24.47%|
Volatility & Risk
Acasti Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Acasti Pharma’s competitors have a beta of 1.17, suggesting that their average share price is 17% more volatile than the S&P 500.
Insider and Institutional Ownership
2.3% of Acasti Pharma shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.4% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Acasti Pharma competitors beat Acasti Pharma on 7 of the 13 factors compared.
About Acasti Pharma
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.